Buck Marcia L, Wiggins Barbara S, Sesler Jefferson M
Department of Pharmacy Servicess, University of Virginia Health System, Charlottesville, VA 22908, USA.
Ann Pharmacother. 2007 Oct;41(10):1679-86. doi: 10.1345/aph.1K168. Epub 2007 Aug 14.
To review and assess the available literature on the use of intraosseous (IO) drug administration during cardiopulmonary resuscitation, addressing the benefits and risks of using this method of drug delivery in children and adults.
The MEDLINE (1950-July 2007) database was searched for pertinent abstracts, using the key term intraosseous infusions. Additional references were obtained from the bibliographies of the articles reviewed. Manufacturer Web sites were used to obtain information about IO insertion devices.
All available English-language clinical trials, retrospective studies, and review articles describing IO drug administration were reviewed. Studies conducted in animal models to evaluate the effectiveness and safety of IO drug administration were also included.
IO access uses the highly vascularized bone marrow to deliver fluids and medications during cardiopulmonary resuscitation. This route, developed in the 1940s, has been revived in the past decade as a means of achieving rapid vascular access when intravenous access cannot be obtained. The primary advantage of IO access is the high success rate (approximately 80%). Most trained providers can place an IO line within 1-2 minutes. A number of small-scale studies and retrospective reviews have established the usefulness of this route for the delivery of many commonly used resuscitation drugs. In addition, animal models have demonstrated rapid drug delivery to the systemic circulation. While all resuscitation drugs can be given by the IO route, administration of ceftriaxone, chloramphenicol, phenytoin, tobramycin, and vancomycin may result in lower peak serum concentrations. The most common adverse effect seen with IO use, extravasation, has been reported in 12% of patients. Compartment syndrome, osteomyelitis, and tibial fracture are rare, but have also been reported.
IO administration is a safe and effective method for delivering drugs during cardiopulmonary resuscitation. It should be considered whenever intravenous access cannot be rapidly obtained.
回顾和评估关于在心肺复苏期间使用骨内(IO)给药的现有文献,探讨在儿童和成人中使用这种给药方法的益处和风险。
使用关键词“骨内输注”在MEDLINE(1950年 - 2007年7月)数据库中检索相关摘要。通过查阅所审查文章的参考文献获取其他资料来源。利用制造商网站获取有关IO插入装置的信息。
审查了所有可用的描述IO给药的英文临床试验、回顾性研究和综述文章。还纳入了在动物模型中评估IO给药有效性和安全性的研究。
IO通路利用高度血管化的骨髓在心肺复苏期间输送液体和药物。这种方法在20世纪40年代开发,在过去十年中得以复兴,作为在无法获得静脉通路时实现快速血管通路的一种手段。IO通路的主要优点是成功率高(约80%)。大多数经过培训的医护人员能够在1 - 2分钟内放置一根IO导管。一些小规模研究和回顾性综述已证实该途径对许多常用复苏药物给药的有效性。此外,动物模型已证明药物能快速输送到体循环。虽然所有复苏药物都可通过IO途径给药,但头孢曲松、氯霉素、苯妥英、妥布霉素和万古霉素给药后血清峰值浓度可能较低。使用IO最常见的不良反应是外渗,据报道在12%的患者中出现。骨筋膜室综合征、骨髓炎和胫骨骨折很少见,但也有报道。
IO给药是心肺复苏期间给药的一种安全有效的方法。在无法迅速获得静脉通路时均应考虑使用。